Discussion

A novel bioanalytical assay will be presented, which enables the measurement of innovative medicines at ultralow levels in biological fluids and tissues. The assay is up to a factor 1.000 more sensitive than conventional techniques and can be applied in toxicokinetic, pharmacokinetic, microdose and ADME studies in an early stage of drug research and development. The assay is generic and has a short development time and high throughput. It allows working with limited sample volumes and testing of minute amounts of drug compound. The assay enables pharmacokinetic and ADME studies with highly potent compounds and compounds with low bioavailability and short half life. Applications include peptides, proteins, antibodies and conjugates thereof, nanomedicines and oligonucleotides.